Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters
- Conditions
- Alzheimer Disease
- Interventions
- Other: Medical file data extraction
- Registration Number
- NCT03408041
- Lead Sponsor
- Murielle Surquin
- Brief Summary
The early diagnosis of Alzheimer's disease is essential to enable patients to have access to the available treatments. However, there is a delay between the diagnosis and the onset of symptoms, which can range from 1 year to more than 5 years. In clinical practice, the hippocampal volume, measured by the Scheltens index, is currently used as a marker of the progression of the disease.
The purpose of this study is to determine whether the patient's sex, age and ethnicity can influence the delay in the expression of cognitive troubles reported by the family at the first medical consultation, as well as to determine if there is a correlation between the delay reported by the family and the Scheltens index.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 129
Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria
None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Alzheimer Disease Medical file data extraction Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria
- Primary Outcome Measures
Name Time Method Age Between 01-01-2010 and 31-01-2013 Age
Sex Between 01-01-2010 and 31-01-2013 Sex
Ethnic origin Between 01-01-2010 and 31-01-2013 Ethnic origin
Symptoms-diagnose time interval Between 01-01-2010 and 31-01-2013 Interval of time between the apparition of the first symptoms, as reported by the family, and the diagnose.
Scheltens scale Between 01-01-2010 and 31-01-2013 Evaluation of the hippocampal atrophy by means of magnetic resonance imaging. Scale from 0 (normal) to 4.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHU Brugmann
🇧🇪Brussels, Belgium